Hopes soar with promis­ing new DVT drug

Warwick Daily News - - HEALTHY LIVING - Grant McArthur

THE tick­ing time bomb of deep vein throm­bo­sis on longhaul flights may have been dis­armed by Mel­bourne sci­en­tists.

Re­searchers from the Baker Heart and Di­a­betes In­sti­tute have de­vel­oped a new drug with the po­ten­tial to pre­vent clots not only for trav­ellers, but also those at risk of, or dur­ing, a heart at­tack or stroke.

In part­ner­ship with Har­vard Univer­sity, the Mel­bourne re­searchers have shown blood clots can be avoided by us­ing small doses of a pep­tide that can cling to high-risk ar­eas, pre­vent­ing dan­ger­ous dam­age.

Baker In­sti­tute re­searcher Xiaowei Wang said the drug could be given in small doses to pre­vent clots from form­ing, po­ten­tially mak­ing it safer than cur­rent blood-thin­ning and clot-bust­ing med­i­ca­tions that carry a dan­ger of bleed­ing.

“We have the po­ten­tial to not only treat peo­ple who are hav­ing heart at­tack, stroke or deep vein throm­bo­sis, but also to pro­tect the pa­tients who are at a very high risk of th­ese events be­fore they oc­cur,” Pro­fes­sor Wang said.

“You could take it be­fore you fly and, hope­fully, it re­duces your risk of get­ting a deep vein throm­bo­sis.”

An Aus­tralian dies every 12 min­utes from car­dio­vas­cu­lar dis­ease.

The Baker and Har­vard drug has been ge­net­i­cally en­gi­neered to be at­tracted to the platelets that form at the site of a clot – with­out any ef­fect on the rest of a per­son’s blood.

Re­sults of a pre­clin­i­cal trial showed the an­ti­bod­ies clung to high-risk ar­eas and stopped clots form­ing.

Newspapers in English

Newspapers from Australia

© PressReader. All rights reserved.